Approaches To Achieve the Best Possible Outcomes in Myeloma

Published 2019-12-06

Recommendations

07:58

Dr. Mikhael on Challenges, Advances in Multiple Myeloma Treatment
09:31

ASH 2023 | High-risk myeloma
00:20

What is myeloma?
1:01:16

ASH 2023 Myeloma Recap with Dr. Ben Derman
09:52

ASH23: Post ASH Summary | Joseph Mikhael, MD
12:56

ASH23: Perseus Trial: DARA + VRd vs. Vrd Alone in ASCT-Eligible Patients | Pieter Sonneveld, MD, PhD
10:21

ASH23: Impact of Dexamethasone (Dex) Dose Strength on Newly Diagnosed Myeloma | Rahul Banerjee, MD
09:39

ASH23: Iceland’s iStopMM Study on Free Light Chains and MGUS | Thorir Einarsson Long, MD, PhD
10:43

ASH23: Elranatamab Effective in Relapsed Myeloma Post-BCMA CAR-T | Daniel Sherbenou, MD, PhD
04:34

What Is the Future for CAR-T in Multiple Myeloma?
06:43

ASH23: STEM Trial Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy | Adam Cohen, MD
05:10

2023 Innovation and Impact Report | International Myeloma Foundation Reports on Key Wins in Myeloma
00:51

M-POWER | Actor and Artist Ice-T Raises Awareness of Myeloma in the Black Community
01:24

Nick Lenoir: Finding Support and Hope in the Myeloma Community | Insights from a 6-Year Survivor
03:55

Cancer Research at the MRC WIMM
06:54

ASH23: CARTITUDE-2 Trial on Ciltacabtagene Autoleucel in Multiple Myeloma | Jens Hillengass, MD, PhD
07:26

ASH23: Sonrotoclax in Combo with Dexamethasone for Relapsed Myeloma with t(11;14) | Dr. Hang Quach
02:28

Black History Month: Diane Hunter's Empowering Advice on Self-Awareness and Health Advocacy
09:44

ASH23: Relapsed Multiple Myeloma Treatment: GMMG Phase III ReLApsE Trial | Marc Andrea Baertsch, MD
06:40

ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MD

Similar videos